Waiting for your call...

Tel # +88-02-8081258
Mobile # +88-01922997784
Skype: bioxin1

Inhaled drug

Aerodynamic Particle Size Distribution

Products - Inhaled drug

The devices used for inhaled and nasal drug delivery are collectively referred as Orally Inhaled and Nasal Drug Products, OINDPs. The OINDPs comprises Inhalers (metered dose, dry powder and aqueous droplet), Nebulizers (jet, ultrasonic and vibrating mesh) and Nasal (aqueous based, dry powder and propellant based).


Dose Content Uniformity (Within Batch)

Products - Inhaled drug

Dose content uniformity (DCU) is the test which ensures the uniform distribution of active drugs in the MDIs/DPIs/NSPs/Nebulizers of a batch. The same test for Nasal Spray (NSP) is called Spray Content Uniformity (SCU) which is also performed within a batch. The test checks the active drug content of a number of MDIs/DPIs/NSPs/Nebulizers from a batch. For Example, 10 MDI units are randomly collected from a lot. Then the 10 MDIs are actuated in 10 different collection tubes to collect the doses.


Dose Content Uniformity (Within Container)

Products - Inhaled drug

Dose content uniformity through container life is the test which ensures the uniform dose distribution of active drug(s) throughout the life of an MDI/DPI/NSP canister/bottle/container. The same test for Nasal Spray (NSP) is called Single Actuation Content (SAC) through container life. The test checks the active drug(s) content of one (sometimes two or three) MDI/DPI/NSP container(s). For Example, 1 MDI unit is randomly collected from a lot. Then the MDI is actuated 10 times (3 in the beginning + 4 in the middle + 3 at the end) in 10 different collection tubes to collect the doses. These 10 collection tubes containing the actuated doses are then assayed to measure the active drug content. The result of this assay helps to identify if there is any unapproved variation in active drug contents in the tested MDI product throughout its life.


Particle Size Analysis by LASER Diffraction

Products - Inhaled drug

Metered Dose Inhaler (MDI), Dry Powder Inhaler (DPI),Nasal Spray (NSP) and Nebulizer.

Particle Size Distribution is a very important parameter to be tested before drug product release. A correct particle size distribution ensures the bioavailability of the active drug on the target site of action. An unapproved particle size distribution may lead to waste of drug doses and decreased efficacy of the dose. For example, a very fine particle/droplet distribution of Nasal Spray (<10 micron) will deposit more spray droplets in the lungs and gastrointestinal tract than the nasal passageway which is the target site of action. To ensure maximum deposition of the spray droplets in the nasal passageway the particle size should be more than 10 micron. Therefore, particle size distribution analysis is an obligatory test before product release.


Spray Pattern and Plume Geometry

Products - Inhaled drug

Have you ever wondered what shape the spray or aerosol you have really produces from your MDI/DPI or NSP? For a variety of reasons, these drug delivery methods need characterization. Following is a piece of information from CMC guideline on the importance of Spray Pattern and Plume Geometry analysis. Characterization of spray pattern and plume geometry is important for evaluating the performance of the pump. Various factors can affect the spray pattern and plume geometry, including the size and shape of the nozzle, the design of the pump, the size of the metering chamber, and the characteristics of the formulation. Spray pattern testing should be performed on a routine basis as a quality control for release of the drug product. However, the characterization of plume geometry typically should be established during the characterization of the product and is not necessarily tested routinely thereafter.

Ref: "Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products -
Chemistry, Manufacturing, and Controls Documentation"

U.S. Department of Health and Human Services, Food and Drug Administration,
Center for Drug Evaluation and Research (CDER), July 2002.



Bio-Xin Invites You to the 3rd Pharma Bangladesh 2012 International Expo

Dear Sir / Madam,

New technologies are emerging every day. New technologies are replacing older applications for better productivity, accuracy and efficiency. We have a promise to introduce breakthrough technologies in the pharma sector of Bangladesh. In this twenty first century breakthrough technology does not mean overwhelming cost. Our expert, educated selection from the leading manufacturers all over the world ensures the most reasonable costing. We are delighted to invite you in our stall in the 3rd Pharma Bangladesh 2012 International Expo holding on 3-5 May, 2012. Your presence in our stall will give you an overall idea how new technologies can be adopted in place of traditional practices. How we are serving Bangladesh for the betterment of pharmaceutical production and quality. We are looking forward for your kind presence in our stall.



Event: 3rd Pharma Bangladesh 2012 International Expo
Venue: Bangabandhu Int. Conference Centre - Dhaka.
Time: 3rd - 5th May, 2012. Open: 10.00 am to 7.00 pm
Web: www.pharmabangladesh.com

Photo Gallery

Bio-Xin Seminar

Quick Contact
  1. Your Name*
    Invalid Input
  2. Your Email*
    Invalid Input
  3. Contact No.*
    Numbers Only!!!
  4. Subject*
    Invalid Input
  5. Detail Inquiry*
    Invalid Input
  6. Type the TEXT
    Type the TEXT
      RefreshInvalid Input

FOLLOW US Bio-Xin Wordpress Blog

Copyright © 2020 bio-xin.com. All Rights Reserved.

Developed by: Binary Yard